(QTRX) Quanterix - Ratings and Ratios
Instruments, Assays, Reagents, Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 71.1% |
| Value at Risk 5%th | 103% |
| Relative Tail Risk | -11.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -72.48 |
| CAGR/Max DD | -0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.544 |
| Beta | 1.695 |
| Beta Downside | 1.855 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.07% |
| Mean DD | 43.80% |
| Median DD | 49.28% |
Description: QTRX Quanterix December 31, 2025
Quanterix Corporation (NASDAQ:QTRX) is a life-sciences firm that develops and markets digital immunoassay platforms designed to enable ultra-sensitive protein detection for precision health research and diagnostics across North America, Europe, the Middle East, Africa, and the Asia-Pacific.
The company’s flagship instruments include the HD-X (single-plex protein detection), the SR-X (expanded Simoa applications), and the SP-X (planar-array multiplex chemiluminescent immunoassays). Complementary consumables-beads, capture/detector reagents, enzymes, substrates, and replacement parts-are sold alongside custom assay-development and contract-research services such as home-brew assay creation, LDT testing, and Lucent Diagnostic services.
Quanterix primarily serves the neurology, oncology, immunology, and inflammation markets, supplying academic, government, pharmaceutical, biotech, and CRO laboratories through a mix of direct field sales, support organizations, and distributor networks.
Recent performance indicators show QTRX’s Q3-2024 revenue grew ~22% YoY to $45 million, driven by a 35% increase in Simoa-based assay orders and expanding adoption in early-stage oncology biomarker programs. The broader life-sciences tools sector is benefiting from a 12% annual rise in global R&D spend and a secular shift toward ultra-sensitive diagnostics, which underpins Quanterix’s addressable market.
For a deeper dive into how Quanterix’s metrics compare to peers, you might explore ValueRay’s analyst toolkit for additional context.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-95.7m TTM) > 0 and > 6% of Revenue (6% = 7.74m TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA -5.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 120.9% (prev 249.4%; Δ -128.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -65.1m > Net Income -95.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (46.1m) change vs 12m ago 19.80% (target <= -2.0% for YES) |
| Gross Margin 51.07% (prev 57.69%; Δ -6.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.17% (prev 32.24%; Δ -2.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.64 (EBITDA TTM -93.3m / Interest Expense TTM -5.43m) >= 6 (WARN >= 3) |
Altman Z'' -7.93
| (A) 0.35 = (Total Current Assets 233.3m - Total Current Liabilities 77.4m) / Total Assets 444.1m |
| (B) -1.25 = Retained Earnings (Balance) -554.1m / Total Assets 444.1m |
| warn (B) unusual magnitude: -1.25 — check mapping/units |
| (C) -0.25 = EBIT TTM -106.6m / Avg Total Assets 427.6m |
| (D) -4.28 = Book Value of Equity -554.9m / Total Liabilities 129.6m |
| Total Rating: -7.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.66
| 1. Piotroski 0.50pt |
| 2. FCF Yield -33.17% |
| 3. FCF Margin -52.89% |
| 4. Debt/Equity 0.13 |
| 5. Debt/Ebitda -0.02 |
| 6. ROIC - WACC (= -45.87)% |
| 7. RoE -30.53% |
| 8. Rev. Trend 49.65% |
| 9. EPS Trend 18.87% |
What is the price of QTRX shares?
Over the past week, the price has changed by +4.25%, over one month by -12.19%, over three months by +17.14% and over the past year by -43.77%.
Is QTRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QTRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7 | 5.6% |
| Analysts Target Price | 7 | 5.6% |
| ValueRay Target Price | 6 | -9% |
QTRX Fundamental Data Overview January 04, 2026
P/S = 2.3068
P/B = 0.9445
Beta = 1.007
Revenue TTM = 129.0m USD
EBIT TTM = -106.6m USD
EBITDA TTM = -93.3m USD
Long Term Debt = 40.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.41m USD (from shortTermDebt, last quarter)
Debt = 40.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82m USD (from netDebt column, last quarter)
Enterprise Value = 205.7m USD (300.4m + Debt 40.1m - CCE 134.8m)
Interest Coverage Ratio = -19.64 (Ebit TTM -106.6m / Interest Expense TTM -5.43m)
FCF Yield = -33.17% (FCF TTM -68.2m / Enterprise Value 205.7m)
FCF Margin = -52.89% (FCF TTM -68.2m / Revenue TTM 129.0m)
Net Margin = -74.17% (Net Income TTM -95.7m / Revenue TTM 129.0m)
Gross Margin = 51.07% ((Revenue TTM 129.0m - Cost of Revenue TTM 63.1m) / Revenue TTM)
Gross Margin QoQ = 42.65% (prev 46.12%)
Tobins Q-Ratio = 0.46 (Enterprise Value 205.7m / Total Assets 444.1m)
Interest Expense / Debt = 30.88% (Interest Expense 12.4m / Debt 40.1m)
Taxrate = 6.89% (-2.48m / -36.0m)
NOPAT = -99.2m (EBIT -106.6m * (1 - 6.89%)) [loss with tax shield]
Current Ratio = 3.02 (Total Current Assets 233.3m / Total Current Liabilities 77.4m)
Debt / Equity = 0.13 (Debt 40.1m / totalStockholderEquity, last quarter 314.5m)
Debt / EBITDA = -0.02 (negative EBITDA) (Net Debt 1.82m / EBITDA -93.3m)
Debt / FCF = -0.03 (negative FCF - burning cash) (Net Debt 1.82m / FCF TTM -68.2m)
Total Stockholder Equity = 313.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.54% (Net Income -95.7m / Total Assets 444.1m)
RoE = -30.53% (Net Income TTM -95.7m / Total Stockholder Equity 313.4m)
RoCE = -30.15% (EBIT -106.6m / Capital Employed (Equity 313.4m + L.T.Debt 40.1m))
RoIC = -31.66% (negative operating profit) (NOPAT -99.2m / Invested Capital 313.4m)
WACC = 14.20% (E(300.4m)/V(340.5m) * Re(12.26%) + D(40.1m)/V(340.5m) * Rd(30.88%) * (1-Tc(0.07)))
Discount Rate = 12.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.34%
Fair Price DCF = unknown (Cash Flow -68.2m)
EPS Correlation: 18.87 | EPS CAGR: 20.25% | SUE: 2.94 | # QB: 1
Revenue Correlation: 49.65 | Revenue CAGR: 7.81% | SUE: 0.90 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.45 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.53 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+31.6% | Growth Revenue=+26.9%
Additional Sources for QTRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle